Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abiomed: Cardiologists Will Respond To Positive Trends In Unfinished Impella Trial

This article was originally published in The Gray Sheet

Executive Summary

Abiomed expects accelerated adoption of its Impella 2.5 circulatory support device based on partial data from a large study evaluating the system in high-risk, non-emergency angioplasty patients, despite having to stop the trial because it was deemed unlikely to meet its endpoint.

You may also be interested in...



FDA Warns Abiomed About Unlawful Promotion Of Impella Cardiac Pump

FDA says Abiomed is promoting its top-selling Impella 2.5 cardiac pump for unapproved uses, and sent a warning letter to the firm June 10.

FDA Warns Abiomed About Unlawful Promotion Of Impella Cardiac Pump

FDA says Abiomed is promoting its top-selling Impella 2.5 cardiac pump for unapproved uses, and sent a warning letter to the firm June 10.

Abiomed Makes Its Case For Impella In High-Risk Angioplasty Cases

Abiomed and its PROTECT II trial principal investigator say they are confident that a partial analysis of the halted study presented April 3 will be enough to get Impella-based circulatory support into cardiology guidelines as a recommended tool for high-risk angioplasties.

Related Content

Topics

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel